Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025 In parallel to evaluating azelaprag, Company will continue to advance earlier ...

On Friday, BioAge Labs Inc. (NASDAQ:BIOA) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag. STRIDES was being conducted in ...

Strides Pharma reiterated its guidance that US sales will reach $400 million by financial year 2028. Its margins also expanded from the same quarter last year. The stock has surged in response.

Strides Pharma has obtained the Food and Drug Administration’s approval for two generics. Strides’ subsidiary, Strides Pharma Global, Singapore, has received approval from the FDA for Sodium Sulphate, ...

RICHMOND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...